

CONTRACEPTION

AUTHOR INDEX

Volume 28

July - December 1983

- | | |
|-------------------------|---------------------------|
| Abdel-Rahman, H., 41 | Chan, P.H., 481 |
| Adams, M.R., 253 | Chan, S.Y.W., 481 |
| Åhrén, T., 315, 341 | Channiyom, K., 61 |
| Aird, S.A., 69 | Chaudhury, M.R., 171 |
| Allen, W.L., 53 | Chi, I.-c, 437 |
| Andersen, O., 489 | Chompootawee, S., 399 |
| Andolsék, L., 505 | Clarkson, T.B., 253 |
| Aono, T., 87 | Colombo, G., 159 |
| Arieli, S., 349 | Confino, E., 521 |
| Åstedt, B., 181, 553 | Contractor, N.M., 527 |
| Back, D.J., 53, 69 | Croxatto, H.B., 543 |
| Bagni, B., 201 | David, M.P., 521 |
| Ballejo, G., 413 | Dechavanne, M., 357 |
| Barke, J.I., 233 | Defoort, P., 299 |
| Barna, P., 233 | Derom, R., 299 |
| Bassi, P., 201 | Diaz, S., 543 |
| Baulieu, E.E., 77 | Diaz-Flores, M., 93 |
| Bergamini, C., 201 | Donde, U.M., 423 |
| Bergquist, C., 225 | Diczfalussy, E., 21 |
| Betrabet, S.D., 423 | Durán, G., 93 |
| Bianchi, A., 201 | Dusitsin, N., 399 |
| Black, C., 103 | Elder, M.G., 405 |
| Boonsiri, B., 61 | El Sahwi, S.Y., 41 |
| Bordekar, A., 527 | Etchepareborda, J.J., 475 |
| Breckenridge, A.M., 53 | Feldblum, P.J., 437 |
| Brenner, P.F., 111, 135 | Ford, S.A., 565 |
| Bukovsky, I., 349 | Fotherby, K., 405 |
| Candini, G.C., 201 | Frances, M., 455 |
| Caspi, E., 349 | Fraser, I.S., 385 |
| Casslén, B., 181, 553 | Galliani, G., 159 |
| Cavallini, A.R., 201 | Goebelsmann, U., 241 |

CONTRACEPTION

- Goh, T.H., 329
 Gommaa, A.A., 149
 Grimmer, S.F.M., 53, 69
 Gross, M., 587
 Guichardant, M., 357
 Hariharan, M., 329
 Hattikudur, N., 527
 Henzl, M., 241
 Hicks, J.J., 93
 Hildebrandt, R., 209
 Hilgers, R., 209
 Hingorani, V., 223
 Houghton, V.P., 103
 Hsueh, A.J.W., 77
 ICMR Task Force on Female
 Sterilization, 369
 ICMR Task Force Study on Regula-
 tion of Male Fertility (Surgical
 Approaches), 423, 527
 Ingram, P., 543
 Ismajovich, B., 521
 Jackanicz, T.M., 315
 Johannisson, E., 21
 Johansson, E.D.B., 315
 Jones, A.R., 565
 Jordan, N., 337
 Kambo, I., 423, 527
 Kesserü, E., 475
 Khan-Dawood, F.S., 413
 Kinra, G., 223
 Kopikar, D.G., 423
 Kovačić, J., 505
 Kovacs, G.T., 455
 Kožuh, M., 505
 Kuhl, H., 587
 Kuhn, W., 209
 Kumar, S., 223
 Lagarde, M., 357
 Landgren, B.-M., 21
 Laufe, L., 299
 Lindgren, P.-G., 225
 Ling, T., 241
 Lithell, H., 315
 Litt, B., 505
 Lohiya, N.K., 281, 575
 Loo, J.C.K., 337
 Luzzani, F., 159
 Marrs, R.P., 111
 Mehliis, W., 587
 Mehta, A., 527
 Mehta, S., 423, 527
 Méndez, J.D., 93
 Menzies, J.A., 337
 Meyer, D., 209
 Mishell, D.R., Jr., 111
 Miyakawa, I., 241
 Miyake, A., 87
 Mollica, G., 201
 Moo-Young, A.J., 253
 Mroszczak, E.J., 241
 Muggeridge, J., 405
 Nelson, C.A., 253
 Orme, M.C.L'E., 53, 69
 Osman, F.H., 149
 Pansini, F., 201
 Parewijck, W., 299
 Pholpramool, C., 273
 Pine, S., 233
 Qunicy, Cl., 357
 Rath, W., 209
 Reinprayoon, D., 399
 Rivero, L.V., 475
 Robertson, D.N., 543
 Roy, S., 111

CONTRACEPTION

- Rudel, L.L., 253
 Rudick, A., 521
 Runkel, R., 241
 Saleem, T.H., 413
 Saleh, F.M., 41
 Sallam, H.N., 41
 Sassolas, A., 357
 Saxena, B.N., 423, 527
 Schneider, D., 349
 Schneider, M., 587
 Schreiber, J.R., 77
 Schreyer, P., 349
 Schwan, A., 341
 Sema, S., 223
 Shahani, S.K., 527
 Sharma, O.P., 575
 Sharma, R.C., 281
 Shaw, M.A., 69
 Shelburne, J.D., 543
 Shikary, Z., 423
 Sizto, R., 189
 Skouby, S.O., 489
 Smith, R.P., 189
 Somboonsuk, A., 399
 Souka, A.-R., 41
 Spellacy, W.N., 413
 Srikhao, A., 273
 Stanczyk, F.Z., 241
 Stegmüller, M., 587
 Tang, G.W.K., 481
 Tang, L.C.H., 481
 Tasaka, K., 87
 Taubert, H.-D., 587
 Tatum, A.H., 543
 Thau, R.B., 253
 Thiery, M., 299
 Tjia, J., 53
 Toddyvalla, V., 21, 423
 Topozada, H.K., 41
 Towobola, O., 405
 Tsibris, J.C.M., 413
 Van Der Pas, H., 299
 Van Kets, H., 299
 Vessby, B., 315
 Victor, A., 315, 341
 Virutamasen, P., 61, 399
 Wagner, H.H., 489
 Watanabe, H., 337
 Weber, W., 587
 Weinraub, Z., 349
 Wilks, J.W., 267
 Wongsrichanalai, C., 61
 WHO Task Force on Long-Acting
 Agents for the Regulation of
 Fertility, 1
 Yedwab, G., 521
 Zito, V., 201

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

1900

SUBJECT INDEX Volume 28 July - December 1983

- Acceptability, vaginal spermicides in combination with barrier methods or IUCD, 103
- Accessory sex organ weights, effect of sulfasalazine (rat), 273
- Acetaminophen-induced hepatic necrosis, effect on pharmacokinetics of levonorgestrel (mouse), 149
- Acid phosphatase level, effect of polyphlorethin phosphate and polyethylene IUD (rat), 171
- Age, influence on blood prolactin levels, 201
- Age at time of vasectomy, long-term effects on antibodies to spermatozoa, 527
- Albumen level, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Alkaline phosphatase level,
 - effect of polyphlorethin phosphate and polyethylene IUD (rat), 171
 - effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Amenorrhoea,
 - effect of depot-medroxyprogesterone acetate, 1
 - effect of norethisterone enanthate, 1
 - survey of different approaches to management during injectable contraceptive use, 385
- Anaesthetic complications following tubal sterilization, 369
- Androgen receptor, binding of RU-486 (rat), 77
- Androgenicity, effect of cyproterone acetate + testosterone enanthate (monkey), 575
- Androgens, effect on thymus and spleen (rat), 587
- Antibodies to spermatozoa, long-term effects of vasectomy, 527
- Antifertility effect, sulfasalazine (rat), 273
- Antifertility studies, α -difluoromethylornithine (hamster), 159
- Apolipoproteins,
 - effect of CVRs releasing different progestins, 315
 - effect of megestrol acetate, 315
- Apoprotein B level, effect of ethinyl estradiol + levonorgestrel, 357
- Bacteriology of vagina,
 - effect of estradiol + levonorgestrel CVR, 341
 - effect of ethinylestradiol + levonorgestrel, 341
- Bilirubin level, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Billings natural family planning method, correlation of subjective signs with cervical mucus quality and ovulation, 475
- Binding to ovarian steroid receptors, RU-486 (rat), 77
- Biochemical constituents of epididymis, effect of danazol + testosterone enanthate (rabbit), 281
- Biochemical constituents of seminal plasma, effect of danazol + testosterone enanthate (rabbit), 281
- Biochemical parameters, long-term effects of vasectomy, 423
- Bioequivalence comparisons of solution and tablet dose, ethinylestradiol + norethindrone, 241
- Bleeding control,
 - effect of CVRs releasing different progestins, 315
 - effect of megestrol acetate, 315

CONTRACEPTION

- Bleeding disturbances, survey of different approaches to management during injectable contraceptive use, 385
- Bleeding pattern,
 - effect of depot-medroxyprogesterone acetate, 1
 - effect of norethisterone enanthate, 1
 - effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 125
- Blood clotting factors, effect of ethinyl estradiol + levonorgestrel, 489
- Blood loss, cervical dilatation prior to vacuum aspiration with laminaria tent, isapent or 15-methyl-PGF₂α, 223
- Blood pressure,
 - effect of depot-medroxyprogesterone acetate, 1
 - effect of ethinyl estradiol + levonorgestrel, 489
 - effect of levonorgestrel CVR (monkey), 253
 - effect of norethisterone enanthate, 1
 - effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Blood urea nitrogen level, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Body weight,
 - effect of depot-medroxyprogesterone acetate, 1
 - effect of ethinyl estradiol + levonorgestrel, 489
 - effect of norethisterone enanthate, 1
 - effect of d-norgestrel, 61
 - effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Calcium level, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Carbon dioxide insufflation omission, laparoscopic tubal ligation, 233
- Carcinoma *in situ* of cervix, effect of oral contraceptives, 505
- Cell-mediated immune response, long-term effects of vasectomy, 527
- Cellular radioimmunoassay, long-term effects of vasectomy, 527
- Cervical dilatation prior to vacuum aspiration, laminaria tent, isapent or 15-methyl-PGF₂α, 223
- Cervical mucus ferning vs. vulvar humidity degree, Billings natural family planning method, 475
- Cervical mucus quality and ovulation correlated with subjective signs, Billings natural family planning method, 475
- Cervical mucus spinnbarkeit vs. vulvar humidity degree, Billings natural family planning method, 475
- Cervix, influence of oral contraceptives on incidence of premalignant and malignant lesions, 505
- Cesarean hysterectomy,
 - post-operative complications, 349
 - subsequent gynecological surgery, 349
- Cesarean section with tubal ligation,
 - post-operative complications, 349
 - subsequent gynecological surgery, 349
- Chloride level, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- 6α-Chloro-1,2α-methylene-17α-hydroxy-pregna-4,6-diene-3,20-dione-17-acetate (cyproterone acetate)
- (R,S)-α-Chlorohydrin (3-chloropropan-1,2-diol)
- (R,S)-3-Chlorolactaldehyde, effect on oxidation of fructose by spermatozoa (rabbit), 565
- 3-Chloropropan-1,2-diol ((R,S)-α-chlorohydrin), effect on oxidation of fructose by spermatozoa (rabbit), 565

- Cholesterol distribution among plasma lipoproteins, effect of
levonorgestrel CVR (monkey), 253
- Cholesterol level,
 - effect of CVRs releasing different progestins, 315
 - effect of ethinyl estradiol + levonorgestrel, 357, 489
 - effect of megestrol acetate, 315
 - effect of triphasic ethinyl estradiol + dl-norgestrel, 189
 - long-term effects of vasectomy, 423
- Clinical chemistry, effect of cyproterone acetate + testosterone
enantate (monkey), 575
- Common faults in previous female sterilization studies, 437
- Complete or incomplete abortions, intracervically administered PG gel
preparations, 209
- Complications, vasectomy, 455
- Complications following tubal sterilization, 369
- Conceptus weight, effect of α -difluoromethylornithine (hamster), 159
- Contraceptive action of polyethylene IUD, effect of polyphloreitin
phosphate (rat), 171
- Contraceptive preparations, effect on thymus and spleen (rat), 587
- Contraceptive vaginal rings (CVR),
 - estradiol + levonorgestrel, 315, 341
 - estradiol + medroxyprogesterone acetate, 315
 - estradiol + megestrol acetate, 315
 - estradiol + norethisterone, 315
 - levonorgestrel (monkey), 253
 - progesterone, 315
- Contraceptational effects, α -difluoromethylornithine (hamster), 159
- Copper-I 200, comparison with OM-GA Cu IUCD in clinical trial, 521
- Corpus luteum function, effect of oxytocin (monkey), 267
- Cortisol level, effect of d-norgestrel, 61
- Cotrimoxazole,
 - effect on ethynylestradiol level, 53
 - effect on FSH level, 53
 - effect on levonorgestrel level, 53
 - effect on progesterone level, 53
- Creatinine level, effect of triphasic ethinyl estradiol +
dl-norgestrel, 189
- Culdotomy tubal sterilization, immediate sequelae, 369
- CVR (contraceptive vaginal ring)
- Cyclic phases, effect on endometrial plasminogen activator activity and
concentrations of urokinase and tissue activator, 553
- Cyproterone acetate (6 α -chloro-1,2 α -methylene-17 α -hydroxy-pregna-4,6-
diene-3,20-dione-17-acetate)
- Cyproterone acetate + testosterone enanthate, effects on seminal char-
acteristics, androgenicity and clinical chemistry (monkey), 575
- Cytology of vagina,
 - effect of estradiol + levonorgestrel CVR, 341
 - effect of ethinyestradiol + levonorgestrel, 341
- Danazol, effect on estrogen-induced LH release (rat), 87
- Danazol + testosterone enanthate, structural and functional changes
in epididymis (rabbit), 281
- Delayed complications following tubal sterilization, 369

CONTRACEPTION

- Delta Lippes loop,
 - immediate postplacental insertion, 299
 - residual catgut after use, 299
- Delta loop, early postpartum insertion, 399
- Delta-I IUD, immediate postpartum insertion, 135
- Delta TCu220C,
 - immediate postplacental insertion, 299
 - residual catgut after use, 299
- Depot-medroxyprogesterone acetate, survey of different approaches to management of menstrual disturbances, 385
- Depot-medroxyprogesterone acetate and norethisterone enanthate, multinational comparative clinical trial of long-acting injectable contraceptives, 1
- Determination of success of attempts to terminate early gestation pregnancies with PG vaginal suppositories, 111
- Diaphragm plus spermicidal jelly, user acceptability, 103
- α -Difluoromethylornithine,
 - contragestational effects (hamster), 159
 - effect on embryonic development (rat), 93
- 5 α -Dihydrotestosterone,
 - effect on fertilizing capacity of spermatozoa, 481
 - effect on sperm motility, 481
- Discontinuation, vaginal spermicides in combination with barrier methods or IUCD, 103
- Discontinuation rate,
 - depot-medroxyprogesterone acetate, 1
 - norethisterone enanthate, 1
- Early gestation pregnancy termination with PG vaginal suppositories, methods to determine success of attempts, 111
- Ectopic pregnancies after sterilization, topic for further female sterilization studies, 437
- Electrocardiogram status, long-term effects of vasectomy, 423
- Embryo weight, effect of α -difluoromethylornithine (hamster), 159
- Embryonic development, effect of α -difluoromethylornithine (rat), 93
- Endocrine changes, sequelae of vasectomy, 455
- Endometrial dating, effect of levonorgestrel and ethinyl estradiol, 21
- Endometrial enzyme levels, effect of polyphlorethin phosphate and polyethylene IUD (rat), 171
- Endometrial morphology, effect of levonorgestrel and ethinyl estradiol, 21
- Endometrial plasminogen activator content, effect of oral contraceptives, 181
- Endometrium, occurrence of urokinase and tissue plasminogen activator, 553
- Enzyme-linked immunosorbent assay, long-term effects of vasectomy, 527
- Epidemiological studies, sequelae of vasectomy, 455
- Epididymal sperm reserve, effect of sulfasalazine (rat), 273
- Epididymis, structural and functional changes following danazol + testosterone enanthate (rabbit), 281
- Epididymis weight,
 - effect of danazol + testosterone enanthate (rabbit), 281
 - effect of sulfasalazine (rat), 273
- Estimated day-of ovulation vs. vulvar humidity degree, Billings natural family planning method, 475

- Estradiol,
 - effect on insulin and glucose levels (rat), 413
 - effect on insulin binding in target tissues (rat), 413
- Estradiol + levonorgestrel CVR,
 - effect on ovarian function, bleeding control and serum lipoproteins, 315
 - effect on vaginal bacteriology and cytology, 341
- Estradiol + medroxyprogesterone acetate CVR, effect on ovarian function, bleeding control and serum lipoproteins, 315
- Estradiol + megestrol acetate CVR, effect on ovarian function, bleeding control and serum lipoproteins, 315
- Estradiol + norethisterone CVR, effect on ovarian function, bleeding control and serum lipoproteins, 315
- Estradiol binding, effect of levonorgestrel and ethinyl estradiol, 21
- Estradiol level,
 - effect of estradiol, progesterone or norgestrel treatment (rat), 413
 - effect of estradiol + medroxyprogesterone acetate CVR, 315
 - effect of estradiol + megestrol acetate CVR, 315
 - effect of estradiol + norethisterone CVR, 315
 - effect of levonorgestrel and ethinyl estradiol, 21
 - effect of progesterone CVR, 315
 - effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 125
- Estrogen-induced LH release, effect of danazol (rat), 87
- Estrogens, effect on thymus and spleen (rat), 587
- 17 α -Ethinyl-5 β -estrane-3 α ,17 β -diol, HPLC-RIA method, 337
- Ethinylestradiol + levonorgestrel,
 - effect on vaginal bacteriology and cytology, 341
 - short-term effects on glucose metabolism, plasma lipids and blood clotting factors, 489
- Ethinyl estradiol + dl-norgestrel triphasic, metabolic effects, 189
- Ethinylestradiol and norethindrone, pharmacokinetics when administered in solution and as tablets, 241
- Ethinylestradiol level, effect of ethinylestradiol + norethindrone administered in solution and as tablets, 241
- Ethinyl estradiol pharmacodynamics, effect of vaginal device releasing levonorgestrel, 21
- Ethinylestradiol + levonorgestrel triphasic, effect of cotrimoxazole, 53
- Ethinylestradiol + l-norgestrel, effect on prolactin levels, 201
- Ethinylestradiol level,
 - effect of cotrimoxazole, 53
 - effect of triphasic ethinylestradiol + levonorgestrel, 53
- Expulsion,
 - effect of time from placental delivery to IUD insertion, 135
 - immediate postpartum insertion of Delta-T-IUD, 135
- Expulsion rate,
 - Copper-T 200, 521
 - early postpartum insertion of Lippes loop D or Delta loop, 399
 - immediate postplacental insertion of Delta Lippes loop, Delta TCu220C or TCu220C, 299
 - QM-GA Cu, 521
- Failure rate,
 - topic for further female sterilization studies, 437
 - vasectomy, 455

CONTRACEPTION

- Fasting blood sugar level, effect of triphasic ethinyl estradiol +
dl-norgestrel, 189
- Fatty acid composition, effect of ethinyl estradiol +
levonorgestrel, 357
- Female sterilization studies,
 - common faults in previous studies, 437
 - methodologic considerations, 437
- Ferritin level,
 - effect of laparoscopic sterilization, 329
 - effect of Multiload Cu 250, 329
 - effect of Progestasert, 329
- Fertility index, effect of sulfasalazine (rat), 273
- Fertilizing capacity of spermatozoa, effect of androgens, 481
- First trimester pregnancy termination, intracervically administered
PG gel preparations, 209
- Follicular diameter, effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 125
- Foreign bodies associated with Silastic implants, scanning electron
microscopy and X-ray microanalysis, 543
- Fredrickson classification, long-term effects of vasectomy, 423
- Fructose oxidation by spermatozoa,
 - effect of (R,S)- α -chlorohydrin (rabbit), 565
 - effect of (R,S)-3-chlorolactaldehyde (rabbit), 565
- FSH (follicle stimulating hormone)
- FSH level,
 - effect of cotrimoxazole, 53
 - effect of norethisterone oenanthate, 41
 - effect of triphasic ethynylestradiol + levonorgestrel, 5
- Functional and structural changes in epididymis, effect of danazol +
testosterone enanthate (rabbit), 281
- Glucocorticoid receptor, binding of RU-486 (rat), 77
- Glucose level,
 - effect of estradiol, progesterone or noregestrel treatment
(rat), 413
 - effect of ethinyl estradiol + levonorgestrel, 489
 - effect of levonorgestrel CVR (monkey), 253
 - effect of d-norgestrel, 61
 - long-term effects of vasectomy, 423
- Glucose metabolism, effect of ethinyl estradiol + levonorgestrel, 489
- β -Glucuronidase level, effect of polyphlorethin phosphate and
polyethylene IUD (rat), 171
- Growth hormone level, effect of d-norgestrel, 61
- Gynecologic treatments and surgeries post-sterilization, topic for
further female sterilization studies, 437
- Haematoma broad ligament, complications of tubal sterilization, 369
- Haemoglobin level,
 - effect of laparoscopic sterilization, 329
 - effect of Multiload Cu 250, 329
 - effect of Progestasert, 329
- Haemorrhage, complications of tubal sterilization, 369
- hCG (human chorionadotropin)
- hCG and oxytocin, effect on serum progesterone level (monkey), 267

- β -hCG level,
 - effect of PG vaginal suppository therapy, 111
 - method to determine success of attempts to terminate early gestation pregnancies with PG vaginal suppositories, 111
- HDL (high density lipoprotein)
- HCL cholesterol level,
 - effect of ethinyl estradiol + levonorgestrel, 357
 - effect of levonorgestrel CVR (monkey), 253
 - long-term effects of vasectomy, 423
- Hematological factors, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Hepatic necrosis, effect on pharmacokinetics of levonorgestrel (mouse), 149
- High density lipoprotein (HDL),
 - effect of CVRs releasing different progestins, 315
 - effect of megestrol acetate, 315
- High-performance liquid chromatography-radioimmunoassay (HPLC-RIA),
 - 17 α -ethinyl-5 β -estrane-3 α ,17 β -diol, 337
- Histological study, effect of danazol + testosterone enanthate (rabbit), 281
- HLA antigens, long-term effects of vasectomy, 527
- Hormonal contraceptives and sex steroids, effect on thymus and spleen (rat), 587
- HPLC-RIA (high-performance liquid chromatography-radioimmunoassay)
- Humoral response to spermatozoal antigens, long-term effects of vasectomy, 527
- 2-Hydroxy-5 [[4-(2-pyridinylamino) sulfonyl] azo] benzoic acid (sulfasalazine), antifertility effect (rat), 273
- 17 β -Hydroxy-11 β -(4-dimethylaminophenyl)-17 α -(1-propynyl) estra-4, 9-dien-3-one (RU-486), binding to ovarian steroid receptors (rat), 77
- Hysterectomy vs. tubal ligation, sterilization at time of cesarean section, 349
- Immediate and early complications, topic for further female sterilization studies, 437
- Immediate postpartum insertion, Delta-T-IUD, 135
- Immediate postplacental IUD insertion, sutured and non-sutured models, 299
- Immediate sequelae following tubal sterilization, 369
- Immune complexes, long-term effects of vasectomy, 527
- Immunological changes, sequelae of vasectomy, 455
- Immunological parameters, long-term effects of vasectomy, 527
- Incidence of carcinoma in situ, effect of oral contraceptives, 505
- Incidence rates for cervical lesions, effect of oral contraceptives, 505
- Injectable contraceptive,
 - depot-medroxyprogesterone acetate, 1, 385
 - norethisterone enanthate, 1, 385
 - norethisterone oenanthate, 41, 405
- Insertion of laparoscopic Irocar without use of carbon dioxide gas, 233
- Insulin binding by target tissues, effect of sex steroids (rat), 413

CONTRACEPTION

- Insulin level,
 - effect of estradiol, progesterone or norgestrel treatment (rat), 413
 - effect of ethinyl estradiol + levonorgestrel, 489
 - effect of d-norgestrel, 61
- Intracervically administered PG gel preparations, termination of first trimester pregnancies, 209
- Intranasal contraceptive, D-Ser(TBU)⁶-EA¹⁰-LRH, 125
- Intrauterine administration of α -difluoromethylornithine, effect on embryonic development (rat), 93
- Intrauterine contraceptive device or intrauterine device (IUCD or IUD),
 - Copper-T 200, 521
 - Delta Lippes Loop, 299
 - Delta loop, 399
 - Delta-I, 135
 - Delta TCu220C, 299
 - effect on endometrial plasminogen activator activity and concentrations of urokinase and tissue activator, 553
 - Lippes loop D, 399
 - Multiload Cu 250, 329
 - OM-GA Cu, 521
 - Progestasert, 329
 - TCu220C, 299
 - user acceptability in combination with vaginal spermicides, 103
- Invasive carcinoma of cervix, effect of oral contraceptives, 505
- Iron level, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Isapent, cervical dilatation prior to vacuum aspiration, 223
- IUCD or condom with spermicidal pessaries, user acceptability, 103
- IUCD or IUD (intrauterine contraceptive device or intrauterine device)
- Laminaria tent, cervical dilatation prior to vacuum aspiration, 223
- Laparoscopic sterilization, effect on serum ferritin and blood haemoglobin levels, 329
- Laparoscopic Trocar insertion, without use of carbon dioxide gas, 233
- Laparoscopic tubal ligation, without prior insufflation of carbon dioxide gas, 233
- Laparoscopic tubal sterilization, immediate sequelae, 369
- LDH, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- LDL (low density lipoprotein)
- LDL and HDL properties, effect of levonorgestrel CVR (monkey), 253
- LDL cholesterol level, long-term effects of vasectomy, 423
- LDL-VLDL cholesterol level, effect of ethinyl estradiol + levonorgestrel, 357
- Leucocyte count in vaginal smear, effect of estradiol + levonorgestrel CVR, 341
- Levonorgestrel binding, effect of levonorgestrel and ethinyl estradiol, 21
- Levonorgestrel CVR,
 - effect on ovarian function, bleeding control and serum lipoproteins, 315
 - effect on vaginal bacteriology and cytology, 341
 - influence on plasma lipids and lipoproteins (monkey), 253

- Levonorgestrel level,
 - effect of cotrimoxazole, 53
 - effect of levonorgestrel administration (mouse), 149
 - effect of levonorgestrel and ethinyl estradiol, 21
 - effect of levonorgestrel CVR (monkey), 253
 - effect of triphasic ethynylestradiol + levonorgestrel, 53
 - influence of acetaminophen-induced hepatic necrosis (mouse), 149
- Levonorgestrel pharmacokinetics, influence of acetaminophen-induced hepatic necrosis (mouse), 149
- Levonorgestrel-releasing vaginal device, effect on ethinyl estradiol pharmacodynamics, 21
- LH (luteinizing hormone)
- LH level, effect of norethisterone oenanthate, 41
- LH release by estradiol, effect of danazol (rat), 87
- Libido, effect of cyproterone acetate + testosterone enanthate (monkey), 575
- Lipids, effect on ethinyl estradiol + levonorgestrel, 489
- Lipids and lipoproteins, influence of levonorgestrel CVR (monkey), 253
- Lipoprotein profile,
 - effect of levonorgestrel CVR (monkey), 253
 - long-term effects of vasectomy, 423
- Lipoproteins,
 - effects of CVRs releasing different progestins, 315
 - effect of megestrol acetate, 315
- Lipoproteins and fatty acid composition, effect of ethinyl estradiol + levonorgestrel, 357
- Lippes loop D, early postpartum insertion, 399
- Long-term effects on biochemical parameters, vasectomy, 423
- Long-term effects on immunological parameters, vasectomy, 527
- Low density lipoprotein (LDL),
 - effect of CVRs releasing different progestins, 315
 - effect of megestrol acetate, 315
- LRH (luteinizing hormone-releasing hormone)
- LRH analog, D-Ser(TBU)⁶-EA¹⁰-LRH, 125
- Luteal phase length, effect of oxytocin (monkey), 267
- Male antifertility effect, sulfasalazine (rat), 273
- Male sterilization, review of sequelae, 455
- Malignant lesions of cervix, influence of oral contraceptives, 505
- Maternal serum and milk, norethisterone levels after injection of norethisterone oenanthate, 405
- Medroxyprogesterone acetate CVR, effect on ovarian function, bleeding control and serum lipoproteins, 315
- Medroxyprogesterone acetate level, effect of estradiol + medroxyprogesterone acetate CVR, 315
- Megestrol acetate,
 - effect on ovarian function, bleeding control and serum lipoproteins, 315
 - Silastic implant, 543
- Megestrol acetate CVR, effect on ovarian function, bleeding control and serum lipoproteins, 315
- Megestrol acetate level,
 - effect of estradiol + megestrol acetate CVR, 315
 - effect of oral administration of megestrol acetate, 315

CONTRACEPTION

- Menstrual cycle, influence on blood prolactin levels, 201
- Menstrual disturbances, survey of different approaches to management during injectable contraceptive use, 385
- Menstrual flow, effect of levonorgestrel CVR (monkey), 253
- Menstrual pattern changes, topic for further female sterilization studies, 437
- Metabolic changes, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Metabolic effects of two triphasic formulations containing ethinyl estradiol + dl-norgestrel, 189
- Metabolite of norethindrone, 17α -ethinyl- 5β -estrane- 3α , 17β -diol HPLC-RIA method, 337
- Methodologic considerations in studies on female sterilization, review for clinicians, 437
- Methods to determine success of attempts to terminate early gestation pregnancies with PG vaginal suppositories, 111
- 15-Methyl-PGF $_2\alpha$, cervical dilatation prior to vacuum aspiration, 223
- Milk concentrations of norethisterone, after injection of norethisterone oenanthate, 405
- Milk/serum norethisterone ratio, after injection of norethisterone oenanthate, 405
- Minilaparotomy/laparotomy tubal sterilization, immediate sequelae, 369
- Morphological changes in testes, sequelae of vasectomy, 455
- Mortality associated with sterilization, topic for further female sterilization studies, 437
- Mortality following tubal sterilization, 369
- Multiload Cu 250, effect on serum ferritin and blood haemoglobin levels, 329
- Multinational comparative clinical trial of long-acting injectable contraceptives, norethisterone enanthate and depot-medroxyprogesterone acetate, 1
- Natural family planning method, correlation of subjective signs with cervical mucus quality and ovulation, 475
- Nonoxynol in combination with other vaginal methods of contraception, user acceptability, 103
- Norethindrone and ethinylestradiol, pharmacokinetics when administered in solution and as tablets, 241
- Norethindrone level, effect of ethinylestradiol + norethindrone administered in solution and as tablets, 241
- Norethindrone metabolite, 17α -ethinyl- 5β -estrane- 3α , 17β -diol HPLC-RIA method, 337
- Norethisterone CVR, effect on ovarian function, bleeding control and serum lipoproteins, 315
- Norethisterone enanthate, survey of different approaches to management of menstrual disturbances, 385
- Norethisterone enanthate and depot-medroxyprogesterone acetate, multinational comparative clinical trial of long-acting injectable contraceptives, 1
- Norethisterone level,
 - after injection of norethisterone oenanthate, 405
 - after oral ingestion of norethisterone in cow's milk, 405
 - effect of estradiol + norethisterone CVR, 315

- Norethisterone level in milk, after injection of norethisterone oenanthate, 405
- Norethisterone oenanthate,
 - effect on blood hormone levels, 41
 - norethisterone levels in maternal serum and milk, 405
- Norgestrel,
 - effect on insulin and glucose levels (rat), 413
 - effect on insulin binding in target tissues (rat), 413
- d-Norgestrel, effect on growth hormone and cortisol, 61
- Octoxynol in combination with other vaginal methods of contraception, user acceptability, 103
- Oestradiol-17 β level, effect of norethisterone oenanthate, 41
- Oestrone-3-glucuronide urinary concentration, effect of oral contraceptives, 69
- Oestrone-3-glucuronide/pregnanediol-3 α -glucuronide ratio, effect of oral contraceptives, 69
- OM-GA Cu IUCD, comparison with Copper-T 200 in clinical trial, 521
- Oral contraceptive,
 - ethinylestradiol + levonorgestrel, 341, 357, 489
 - ethinylestradiol + norethindrone, 241
 - ethinylestradiol + 1-norgestrel, 201
 - megestrol acetate, 315
 - mestranol + norethindrone, 337
 - d-norgestrel, 61
 - triphasic ethinyl estradiol + dl-norgestrel, 189
 - triphasic ethinylestradiol + levonorgestrel, 53
- Oral contraceptive users, plasminogen activator content of endometrium, 181
- Oral contraceptives,
 - effect on urinary concentrations of steroid glucuronides, 69
 - influence on blood prolactin levels, 201
 - influence on incidence of premalignant and malignant lesions of cervix, 505
- Ornithine decarboxylase activity, effect of α -difluoromethylornithine (hamster), 159
- Ornithine decarboxylase activity during pregnancy (hamster), 159
- L-Ornithine decarboxylase activity in implantation sites, effect of α -difluoromethylornithine (rat), 93
- Ovarian follicles, effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 125
- Ovarian function,
 - effect of CVRs releasing different progestins, 315
 - effect of megestrol acetate, 315
- Ovarian hormonal reaction, effect of levonorgestrel and ethinyl estradiol, 21
- Ovarian steroid receptors, binding of RU-486 (rat), 77
- Ovulation and cervical mucus quality correlated with subjective signs, Billings natural family planning method, 475
- Oxytocin, effect on corpus luteum function (monkey), 267
- Pattern of pregnancy arrest, α -difluoromethylornithine (hamster), 159
- PG (prostaglandin)
- PG gel preparations, intracervically administered for termination of first trimester pregnancies, 209

CONTRACEPTION

- PGE₂ gel preparation, intracervical application for termination of first trimester pregnancies, 209
- Pharmacodynamic effects of ethinyl estradiol, effect of vaginal device releasing levonorgestrel, 21
- Pharmacokinetics of levonorgestrel, influence of acetaminophen-induced hepatic necrosis (mouse), 149
- Pharmacokinetics of norethindrone and ethinylestradiol, administered in solution and as tablets, 241
- 16-Phenoxy-w-17,18,19,20-tetranor PGE₂ methyl sulfonylamide (Sulprostone)
- Phospholipids level, effect of ethinyl estradiol + levonorgestrel, 357
- Plasminogen activator activity,
effect of cyclic phases and IUD in endometrium, 553
effect of oral contraceptives, 181
- Plasminogen activator content of endometrium, effect of oral contraceptives, 181
- Polarization microscopy, foreign bodies associated with Silastic implants, 543
- Polyethylene IUD, effect of polyphlorethin phosphate on contraceptive action (rat), 171
- Polyphlorethin phosphate, effect on contraceptive action of polyethylene IUD (rat), 171
- Postpartum insertion,
Delta-T IUD, 135
Lippes loop D or Delta loop, 399
- Postplacental insertion, sutured and non-sutured IUDs, 299
- Potassium level, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Pregnancy, immediate postpartum insertion of Delta-T IUD, 135
- Pregnancy rate,
Copper-T 200, 521
depot-medroxyprogesterone acetate, 1
early postpartum insertion of Lippes loop D or Delta loop, 399
immediate postplacental insertion of Delta Lippes loop,
Delta TCu220C or TCu220C, 299
norethisterone enanthate, 1
OM-GA Cu, 521
- Pregnanediol-3 α -glucuronide urinary concentration, effect of oral contraceptives, 69
- Premalignant and malignant lesions of cervix, influence of oral contraceptives, 505
- Progestasert, effect on serum ferritin and blood haemoglobin levels, 329
- Progesterone,
effect on insulin and glucose levels (rat), 413
effect on insulin binding in target tissues (rat), 413
- Progesterone CVR, effect on ovarian function, bleeding control and serum lipoproteins, 315

- Progesterone level,
 - effect of cotrimoxazole, 53
 - effect of α -difluoromethylornithine (hamster), 159
 - effect of estradiol, progesterone or norgestrel treatment (rat), 413
 - effect of estradiol + medroxyprogesterone acetate CVR, 315
 - effect of estradiol + megestrol acetate CVR, 315
 - effect of estradiol + norethisterone CVR, 315
 - effect of levonorgestrel and ethinyl estradiol, 21
 - effect of levonorgestrel CVR (monkey), 253
 - effect of norethisterone oenanthate, 41
 - effect of oxytocin (monkey), 267
 - effect of oxytocin and hCG (monkey), 267
 - effect of progesterone CVR, 315
 - effect of D-Ser(TBU)⁶-EA¹⁰-LRH, 125
 - effect of triphasic ethynylestradiol + levonorgestrel, 53
- Progesterone receptor, binding of RU-486 (rat), 77
- Progestogens, effect on thymus and spleen (rat), 587
- Prolactin level,
 - effect of ethynylestradiol + l-norgestrel, 201
 - effect of norethisterone oenanthate, 41
 - influence of age, menstrual cycle and oral contraceptives, 201
- Prostaglandin (PG),
 - 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 111
 - 15-methyl-PGF₂ α , 223
 - 16-phenoxy-w-17,18,19,20-tetranor PGE₂ methyl sulfonylamide, 209
 - (15S)-15 methyl PGF₂ α methyl ester, 111
- Prostaglandin vaginal suppositories, methods to determine success
 - of attempts to terminate early gestation pregnancies, 111
- Psychological aspects of vasectomy, review, 455
- Putrescine and α -difluoromethylornithine, effect on embryonic
 - development (rat), 93
- Quetelet index, effect of triphasic ethinyl estradiol +
 - dl-norgestrel, 189
- Recommended research methodologies for female sterilization studies,
 - case-control studies of rare events, 437
 - comparative clinical trials for evaluation of immediate
 - and short-term effects, 437
 - prospective (cohort) studies on long-term effects, 437
- Removal rate,
 - Copper-T 200, 521
 - PM-GA Cu, 521
- Residual catgut, after Delta Lippes loop or Delta TCu220C use, 299
- Reversibility of vasectomy, review, 455
- Route of sterilization, effect on prognosis, 369
- RU-486 (17 β -hydroxy-11 β -(4-dimethylaminophenyl)-17 α -(1-propynyl)
 - estra-4,9-dien-3-one)
- Scanning electron microscopy, foreign bodies associated with Silastic
 - implants, 543
- Seminal characteristics,
 - effect of cyproterone acetate + testosterone enanthate (monkey), 575
 - effect of danazol + testosterone enanthate (rabbit), 281
- Sepsis, complications of tubal sterilization, 369
- Sequelae, immediately following tubal sterilization, 369

CONTRACEPTION

- Sequelae of male sterilization, review, 455
- D-Ser(TBU)⁶-EA¹⁰-LRH, effect on ovarian follicles, 125
- Severe dysplasia of cervix, effect of oral contraceptives, 505
- Sex hormone binding globulin level, effect of levonorgestrel and ethinyl estradiol, 21
- Sex steroids, effect on insulin binding by target tissues (rat), 413
- Sex steroids and hormonal contraceptives, effect on thymus and spleen (rat), 587
- SGOT, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- SGOT level, long-term effects of vasectomy, 423
- Shock, complications of tubal sterilization, 369
- Side effects,
 cervical dilatation prior to vacuum aspiration with laminaria tent, isaptent or 15-methyl-PGF_{2α}, 223
- Copper-T 200, 521
- intracervically administered PG gel preparations, 209
- OMD-GA Cu, 521
- vaginal spermicides in combination with barrier methods or IUCD, 103
- Silastic implants containing megestrol acetate, scanning electron microscopy and X-ray microanalysis of surrounding subcutaneous tissue 543
- Sodium level, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- Sperm count, effect of danazol + testosterone enanthate (rabbit), 281
- Sperm motility,
 effect of danazol + testosterone enanthate (rabbit), 281
- effect of 5α-dihydrotestosterone, 481
- effect of sulfasalazine (rat), 273
- effect of testosterone, 481
- Spermatozoa immobilization test, long-term effects of vasectomy, 27
- Spermatozoal capacitation, effect of androgens, 481
- Spermatozoal oxidation of fructose,
 effect of (R,S)-α-chlorohydrin (rabbit), 565
- effect of (R,S)-3-chlorolactaldehyde (rabbit), 565
- Spermicides in combination with barrier methods or IUCD,
 user acceptability, 103
- Spleen and thymus, effect of sex steroids and hormonal contraceptives, (rat), 587
- Sterilization,
 cesarean hysterectomy, 349
- cesarean section with tubal ligation, 349
- culdotomy tubal occlusion, 369
- laparoscopic tubal ligation without prior insufflation of carbon dioxide gas, 233
- laparoscopic tubal occlusion, 329, 369
- mililaparotomy/laparotomy tubal occlusion, 369
- Sterilization at time of cesarean section, tubal ligation vs. hysterectomy, 349
- Steroid glucuronides, effect of oral contraceptives on urinary concentrations, 69
- Steroid receptors, binding of RU-486 (rat), 77
- Structural and functional changes in epididymis, effect of danazol + testosterone enanthate (rabbit), 281

- Subcutaneous tissue around Silastic implant containing megestrol acetate, scanning electron microscopy and X-ray microanalysis, 543
- Subjective signs correlated with cervical mucus quality and ovulation, Billings natural family planning method, 475
- Sulfasalazine (2-hydroxy-5 [[4-(2-pyridinylamino) sulfonyl] azo] benzoic acid)
- Sulprostone (16-phenyloxy-w-17,18,19,20-tetranor PGE₂ methyl sulfonylamide)
- Sulprostone gel preparation, intracervical application for termination of first trimester pregnancies, 209
- Survey of different approaches to management of menstrual disturbances during injectable contraceptive use, 385
- Sutured and non-sutured models, immediate postplacental IUD insertion, 299
- TC (total cholesterol)
- TC level, effect of ethinyl estradiol + levonorgestrel, 357
- TC/HDL cholesterol, effect of ethinyl estradiol + levonorgestrel, 357
- TCu220C, immediate postplacental insertion, 299
- Termination, immediate postpartum insertion of Delta-T IUD, 135
- Termination of early gestation pregnancies with PG vaginal suppositories, methods to determine success of attempts, 111
- Termination of first trimester pregnancy, intracervically administered PG gel preparations, 209
- Termination rate,
 - early postpartum insertion of Lippes loop D or Delta loop, 399
 - immediate postplacental insertion of Delta Lippes loop, Delta TCu220C or TCu220C, 299
- Testicular changes following vasectomy, 455
- Testis weight, effect of sulfasalazine (rat), 273
- Testosterone,
 - effect on fertilizing capacity of spermatozoa, 481
 - effect on sperm motility, 481
- Testosterone binding, effect of levonorgestrel and ethinyl estradiol, 21
- Testosterone enanthate + cyproterone acetate, effects on seminal characteristics, androgenicity and clinical chemistry (monkey), 575
- Testosterone enanthate + danazol, structural and functional changes in epididymis (rabbit), 281
- Testosterone level,
 - effect of cyproterone acetate + testosterone enanthate (monkey), 575
 - effect of sulfasalazine (rat), 273
- Thrombophlebitis, complications of tubal sterilization, 369
- Thymus and spleen, effect of sex steroids and hormonal contraceptives (rat), 587
- Time from placental delivery to IUD insertion, effect on expulsion, 135
- Time of sterilization, effect on prognosis, 369
- Tissue activator level,
 - effect of cyclic phases and IUD in endometrium, 553
 - effect of oral contraceptives, 181
- Tissue passed by histology, method to determine success of attempts to terminate early gestation pregnancies with PG vaginal suppositories, 111
- Tissue passed by history, method to determine success of attempts to terminate early gestation pregnancies with PG vaginal suppositories, 111
- Tissue plasminogen activator and urokinase in endometrium, 553

CONTRACEPTION

- Tonometric examination of cervical canal, effect of intracervically administered PG gel preparations, 209
- Total protein level, effect of triphasic ethinyl estradiol + dl-norgestrel, 189
- TPC (total plasma cholesterol)
- TPC level, effect of levonorgestrel CVR (monkey), 253
- TPC:HDL cholesterol ratio, effect of levonorgestrel CVR (monkey), 253
- Tray agglutination test, long-term effects of vasectomy, 527
- Triglycerides level,
 - effect of CVRs releasing different progestins, 315
 - effect of ethinyl estradiol + levonorgestrel, 357, 489
 - effect of levonorgestrel CVR (monkey), 253
 - effect of megestrol acetate, 315
 - effect of triphasic ethinyl estradiol + dl-norgestrel, 189
 - long-term effects of vasectomy, 423
- Tubal ligation vs. hysterectomy, sterilization at time of cesarean section, 349
- Tubal sterilization, immediate sequelae, 369
- Uric acid level, long-term effects of vasectomy, 423
- Urinary concentrations of steroid glucuronides, effect of oral contraceptives, 69
- Urokinase and tissue plasminogen activator in endometrium, 553
- Urokinase level,
 - effect of cyclic phases and IUD in endometrium
 - effect of oral contraceptives, 181
- Use effectiveness,
 - depot-medroxyprogesterone acetate, 1
 - norethisterone enanthate, 1
- Uterine cramps, effect of intracervically administered PG gel preparations, 209
- Vacuum aspiration in late first trimester pregnancy, cervical dilatation with laminaria tent, isaptent or 15-methyl-PGF_{2α}, 223
- Vaginal bacteriology and cytology,
 - effect of estradiol + levonorgestrel CVR, 341
 - effect of ethinylestradiol + levonorgestrel, 341
- Vaginal bleeding, intracervically administered PG gel preparations, 209
- Vaginal device, releasing levonorgestrel, 21
- Vaginal PG suppositories, methods to determine success of attempts to terminate early gestation pregnancies, 111
- Vaginal spermicides in combination with barrier methods or IUCD, user acceptability, 103
- Vasectomy,
 - complications, 455
 - endocrine changes, 455
 - epidemiological studies, 455
 - failure rate, 455
 - immunological changes, 455
 - long-term effects on biochemical parameters, 423
 - long-term effects on immunological parameters, 527

CONTRACEPTION

- morphological changes in testes, 455
- psychological aspects, 455
- reversibility, 455
- review of sequelae, 455
- types of operations, 455
- Very low density lipoprotein (VLDL),
 - effect of CVRs releasing different progestins, 315
 - effect of megestrol acetate, 315
- Visceral injury, complications of tubal sterilization, 369
- VLDL (very low density lipoproteins)
- VLDL + LDL + LDL cholesterol level, effect of levonorgestrel
CVR (monkey), 253
- Vulvar humidity degree vs. cervical mucus ferning, Billings
natural family planning method, 475
- Vulvar humidity degree vs. cervical mucus spinnbarkeit, Billings
natural family planning method, 475
- Vulvar humidity degree vs. estimated day of ovulation, Billings
natural family planning method, 475
- Wound healing, complications of tubal sterilization, 369
- X-ray microanalysis, foreign bodies associated with Silastic implants, 543

